Price movement over the last 24 hours
AMETEK, Inc. vs GeneDx Holdings Corp — how do they compare? AMETEK, Inc. trades at $235.14 (market cap $53.63B), while GeneDx Holdings Corp trades at $65.06 (market cap $1.95B). The key difference: AMETEK, Inc. is far larger — about 27.5× GeneDx Holdings Corp's market cap, and AMETEK, Inc. pays a 0.58% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| AME | WGS | |
|---|---|---|
Market Cap | $53.63B | $1.95B |
Sector | Industrials | Technology |
52-Week High | $241.94 | $167.51 |
52-Week Low | $176.44 | $34.51 |
Enterprise Value | $55.33B | $1.95B |
Dividend Yield | 0.58% | — |
Signals from Pluang's Aura AI — not financial advice
AME trades at $233.98, up 0.42% today, with a neutral technical signal and strong fundamentals including three consecutive quarterly EPS beats. The company maintains robust profitability with a 20.11% net margin and recently completed the acquisition of First Aviation Services, expanding its aerospace and defense footprint. Cash flow remains positive with $83.95M net inflow in 2025.
Outlook is positive with a $260 consensus price target representing 11% upside, supported by 68.97% analyst buy ratings. Risks include elevated P/E of 35.34 and integration challenges from recent acquisitions. The stock offers growth exposure to industrial technology and aerospace sectors with stable dividend payments.
GeneDx Holdings (WGS) trades at $65.64, down 5.4% over 24 hours, with a bullish technical signal from moving averages. The company reported revenue of $427.54 million in 2025 but a net loss of $21.02 million, with profitability metrics like ROE at -30.42% indicating financial strain. Recent news highlights a securities class action lawsuit filed against the company, alleging misleading statements related to the Fabric Genomics acquisition.
While analyst consensus remains strongly bullish with a $75.40 price target, the stock faces significant risks from ongoing litigation and persistent losses. Investment appeal hinges on the company's ability to improve margins and navigate legal challenges, but current fundamentals suggest caution despite optimistic Wall Street ratings.
Trailing returns across standard periods
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →